Tiny study eyes safety of TALZENNA in tough prostate cancer
NCT ID NCT06733337
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tracks the safety of the drug TALZENNA in one man with a specific type of advanced prostate cancer that has a BRCA gene mutation and no longer responds to hormone therapy. The participant takes TALZENNA as prescribed and is monitored for side effects for up to a year. Because it involves only one person and focuses on safety, it cannot tell us whether the drug works well.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TALZENNA (talazoparib)
- What this could lead to
- If successful, this study could confirm that TALZENNA is safe enough to use more widely for this type of prostate cancer.
- What could go wrong
- This is a very small study (only 1 person) focused on safety, not effectiveness. It cannot prove the drug works or is safe for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA MUTATION-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Japan
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?